Fresh analysis reveals that patients who stop using blockbuster slimming jabs like Wegovy and Mounjaro may regain lost weight much more quickly than those who end traditional diet and exercise regimens.
Findings released in a prominent health publication points out that while obese individuals can lose about a fifth of their body weight while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users using such treatments need to be cognizant of the danger of quick weight regain when the treatment ends," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original weight in about 18 months.
Analyzing Treatments
The research, which examined dozens of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists note that people who lose weight through dieting generally experience a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Nutrition scientists believe the way of the drugs accounts for the heightened regain.
These medications copy a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than normal might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Issue?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the treatment is often life-long.
This opinion is supported by drug manufacturers, who state that the results "highlight the chronic character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have come off the medication explain a intense resurgence of hunger.
"It felt as if something that goes on and you're instantly starving," said a patient.
This challenge is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Widespread Use
Figures show that a significant number of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Use is greater among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic fix and lasting health benefits hinges on integrated behavioural support.
